Description

• An oral oxazolidinone-based anticoagulant agent.
• It inhibits not only free factor Xa with high selectivity but also prothrombinase bound and clot-associated factor Xa in a concentration-dependent manner.
• It is a potent, selective direct inhibitor of factor Xa that is used in the prevention of venous thromboembolism (VTE) in adult patients after total hip replacement (THR) or total knee replacement (TKR) surgery.
• For a 10 mg dose, the oral bioavailability of Rivaroxaban is high (80–100%) and is not affected by food intake.
• The drug is metabolized to inactive metabolites in liver, half of which is excreted by kidneys and other half is excreted via faecal route.